Trial Profile
A phase I/IIa basket study of an adoptive T-cell therapy for cancer treatment
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2017
Price :
$35
*
At a glance
- Drugs Adoptive-T-cell-therapy-Tactiva-Therapeutics (Primary) ; Decitabine
- Indications Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Tactiva Therapeutics
- 08 Dec 2017 New trial record